zzlangerhans’ Activity

Wed Jan 7

CAPS Outperform Pitch Reply

zzlangerhans commented on zzlangerhans's pitch for GALT. 8:28 AM

Sold all 2000 shares at 4.8 pre-market for profit of $1220.

CAPS Outperform Pitch

zzlangerhans wrote about INVIVO THERAPEUTICS (NVIV) . 4:09 AM

NVIV Outperform

I might as well try and jump into this hyped-up run-up rather than trying to hold back the tsunami with my bare hands. As I've described in the past, InVivo has a very checkered history that I won't bother to rehash. After crashing from a hyped up [more]

Tue Jan 6

Caps Pick

zzlangerhans made a pick in CAPS. 11:13 AM

INVIVO THERAPEUTICS (NVIV) will Outperform the S&P 500

CAPS Underperform Pitch

zzlangerhans wrote about Vermillion, Inc. (VRML) . 8:46 AM

VRML Underperform

Vermillion has become an interesting combination of the predictable and the unpredictable. What's predictable? Revenues will be flat and the company will burn cash every quarter. What's unpredictable? The share price. Ever since the stock rose from 1 [more]

CAPS Underperform Pitch

zzlangerhans wrote about Alexza Pharmaceuticals, Inc. (ALXA) . 5:58 AM

ALXA Underperform

Being an ER doctor doesn't really give me much perspective on biopharma stocks, except when I get a chance to ask questions to the oncology consultants and other specialists that roll through the ED. Occasionally there's a product that comes through [more]

Caps Pick

zzlangerhans made a pick in CAPS. 5:58 AM

Alexza Pharmaceuticals, Inc. (ALXA) will Underperform the S&P 500

Mon Jan 5

Caps Pick

zzlangerhans made a pick in CAPS. 3:07 PM

Vermillion, Inc. (VRML) will Underperform the S&P 500

CAPS Outperform Pitch

zzlangerhans wrote about Brainstorm Cell Therapeutics Inc. (BCLI) . 12:58 PM

BCLI Outperform

There are two kinds of traders in biopharma. One looks at a company that seems to have just announced remarkable results in a clinical trial of a novel therapy for ALS but still has a market cap less than 100M and thinks: Opportunity! The other kind [more]

CAPS Underperform Pitch Reply

zzlangerhans commented on zzlangerhans's pitch for MACK. 11:01 AM

Wow, just looked at your track record. Absolutely horrendous. Might want to consider sticking with board games, ages 6-12.

CAPS Underperform Pitch Reply

zzlangerhans commented on superstar's pitch for BCLI. 10:56 AM

Your reply demonstrates clearly why some players get into the high 99's on CAPS and some don't. Stem cell "therapy" does not cure leukemia. Other drugs kill leukemia by killing all bone marrow and then stem cells are used to reconstitute a [more]

Caps Pick

zzlangerhans made a pick in CAPS. 10:40 AM

Brainstorm Cell Therapeutics Inc. (BCLI) will Outperform the S&P 500

Sun Jan 4

CAPS Underperform Pitch

zzlangerhans wrote about Ampio Pharmaceuticals, Inc. (AMPE) . 4:31 AM

AMPE Underperform

It feels a little weird to be red-thumbing Ampio at a level from which they've taken flight many times before, but I think the company will report failure of the phase III trial of Optina in the near future. That should take the share price down [more]

Caps Pick

zzlangerhans made a pick in CAPS. 4:31 AM

Ampio Pharmaceuticals, Inc. (AMPE) will Underperform the S&P 500

CAPS Underperform Pitch

zzlangerhans wrote about ATHERSYS, INC. (ATHX) . 1:21 AM

ATHX Underperform

Athersys is really two stories as a trade. One story is Athersys the company. The second is the retail cult of Athersys. The retail cult causes the share price to gyrate wildly depending on the relative degree of optimism among their ill-informed [more]

Fri Jan 2

Caps Pick

zzlangerhans made a pick in CAPS. 3:47 PM

ATHERSYS, INC. (ATHX) will Underperform the S&P 500

CAPS Underperform Pitch

zzlangerhans wrote about Synageva BioPharma (GEVA) . 3:25 PM

GEVA Underperform

Why not take a smack at two Baker Bros stocks on the same day? Synageva has been a volatile stock over the past two years as enthusiasm over their orphan drug candidate and Baker Bros involvement has alternated with skepticism about the size of the [more]

Caps Pick

zzlangerhans made a pick in CAPS. 2:23 PM

Synageva BioPharma (GEVA) will Underperform the S&P 500

CAPS Underperform Pitch

zzlangerhans wrote about Cerus Corp (CERS) . 4:37 AM

CERS Underperform

Cerus had some positive developments last month, but I think the 50% increase in share price is overly optimistic.

Finally getting FDA approval of the Intercept system for platelets and plasma is an accomplishment, but the system has made [more]

Caps Pick

zzlangerhans made a pick in CAPS. 4:37 AM

Cerus Corp (CERS) will Underperform the S&P 500

Thu Jan 1

CAPS Underperform Pitch Reply

zzlangerhans commented on zzlangerhans's pitch for ADXS. 7:43 PM

Hey, thanks for helping me out. I'll cover as soon as I've made $2000.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 99.81
Player Rank 144 out of 75062
Score 6843.60
Score Change Today -140.59
Accuracy 82.22%
Active Picks 167
Total Picks 2024
Best Pick MDVN (+1396.64)
Worst Pick PCYC (-2886.09)
Average Score per Pick 3.38
Charms Earned 15
Highest Rated Favorite portefeuille
Go to zzlangerhans’ CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show zzlangerhans’ 10 Latest Posts